$SNEX

Dunaway William J sold $8.3M of SNEX

Dunaway William J (Chief Financial Officer) sold 63,602 shares of StoneX Group Inc. (SNEX) at $131.16 ($8.34M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dunaway William J
Published Jun 15, 2026, 11:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SNEX
Neutral
medium confidence
Mentioned
$SNEX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

The CFO’s open-market sale (63,602 shares) is newly disclosed and could slightly influence sentiment, but the presence of a pre-arranged 10b5-1 plan lowers the probability it signals new negative information.

02

Market read

A fresh insider-sale datapoint for SNEX, likely to have only marginal trading impact absent additional fundamental news.

03

What to watch

Traders may overreact to insider sales; the key is whether there are concurrent buys/sales by other insiders or any new company disclosures beyond this Form 4.

Relevance 5/10Novelty 6/10Timing: Filed June 15; sale executed June 12 under a 10b5-1 plan

Background

The article is an SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralMedium confidence
Context

StoneX CFO William J. Dunaway sold 63,602 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any reaction should be small unless accompanied by other new fundamentals.

Evidence & confidence

Form 4 provides a fresh, company-specific ownership-change datapoint, but 10b5-1 pre-arrangement typically indicates planned diversification rather than new information.

Market effects

Minimal; this is a single-company insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/diversification rather than bearish expectations.

Key entities

  • StoneX Group Inc.

    Company whose CFO filed the Form 4 insider sale disclosure.

  • William J. Dunaway

    Chief Financial Officer who sold shares in an open-market transaction.

Related articles

$SNEXMedAI 8/10

StoneX Group Inc. (SNEX): Results of Operations and Financial Condition

StoneX Group Inc. (SNEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 snex2026er_exhq3roll.htm EX-99.1 Document EXHIBIT 99.1 StoneX Group Inc. Reports Fiscal 2026 Third Quarter Financial Results Quarterly Net Operating Revenues of $719.7 million, up 47% Quarterly Net Income of $127.9 million, Quarterly ROE of 18.4% Quarterly Diluted EPS o

$HMRMedAI 8/10

Homerun Resources Inc. Announces up to $15 Million Convertible Security Financing with Lind Partners Under Engagements with Benchmark/Stonex

Homerun Resources Inc. (TSXV:HMR, OTCQB:HMRFF) said it signed a convertible security funding agreement with Lind Global Fund III for up to C$15 million, including a C$2 million initial tranche at closing. The initial convertible has a 24-month term, a C$0.66 fixed conversion price, and 1.6 million warrants. Benchmark is exclusive placement agent.

$HMRMedAI 8/10

Homerun Resources Inc.: Homerun Resources Inc. Announces up to $15 Million Convertible Security Financing with Lind Partners Under Engagements with Benchmark/Stonex

Homerun Resources Inc. (TSXV: HMR, OTCQB: HMRFF) said it signed a convertible security financing with Lind Global Fund III managed by The Lind Partners for up to C$15 million. The initial C$2 million tranche has a 24-month term, six-month repayment holiday, fixed C$0.66 conversion price, and 1.6 million warrants. Benchmark is exclusive placement agent; StoneX is non-exclusive advisor.